Table 3.
Summary of data regarding the prognostic role of PD-L1 in treatment efficacy of EGFR-TKIs.
| Author | Year | Patient number | PD-L1 antibody | Outcome associated with high PD-L1 expression |
|---|---|---|---|---|
| D’Incecco et al.42 | 2015 | 95 | Ab58810 | Better RR and longer TTP |
| Lin et al.43 | 2015 | 56 | Ab58810 | Better DCR and longer PFS |
| Tang et al.41 | 2015 | 64 | E1L3N | No association |
| Soo et al.11 | 2017 | 90 | SP142 | Shorter PFS |
| Yoneshima et al.14 | 2018 | 71 | Dako 22C3 | Shorter PFS |
| Su et al.12 | 2018 | 101 | SP142 | Poor RR, shorter PFS, higher primary resistance rate |
| Hsu et al.8 | 2019 | 123 | SP263 | Shorter PFS, higher primary resistance rate |
| Matsumoto et al.10 | 2019 | 52 | 28-8 | Shorter PFS |
| D7U8C | ||||
| Yang et al.13 | 2020 | 153 | Dako 22C3 | Poor RR, shorter PFS, higher primary resistance rate |
| Yoon et al.15 | 2020 | 131 | Dako 22C3 | Poor RR and shorter PFS |
| Kim et al.44 | 2020 | 69 | SP142 | No association |
| SP263 | ||||
| Dako 22C3 | ||||
| Chang et al.19 | 2021 | 114 | Dako 22C3 | No association |
| Liu et al.9 | 2021 | 186 | SP263 | Shorter PFS |
| Present study | 2022 | 157 | Dako 22C3 | Shorter PFS |
| Associated with BIM expression |
DCR, disease control rate; EGFR, epidermal growth factor receptor; PFS, progression-free survival; RR, response rate; TKIs, tyrosine kinase inhibitors; TTP, time to progression.